Good nilotinib responses in imatinib-resistant AP-CML

News
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 2
Volume 17
Issue 2

Among Ph+ chronic myelogenous leukemia patients in accelerated phase with imatinib (Gleevec) resistance or intolerance, treatment with nilotinib (Tasigna) rapidly produced significant responses and was generally well tolerated in an open-label pivotal phase II study

ATLANTA—Among Ph+ chronic myelogenous leukemia patients in accelerated phase with imatinib (Gleevec) resistance or intolerance, treatment with nilotinib (Tasigna) rapidly produced significant responses and was generally well tolerated in an open-label pivotal phase II study. Philipp le Coutre, MD, of Charite Campus Virchow Klinikum, Berlin, reported the results at ASH 2007 (abstract 471). The study included 136 patients whose median CML duration was 71 months: 80% were imatinib resistant and 20% were imatinib intolerant.

Among the patients who completed at least one nilotinib cycle, Dr. le Coutre said, the hematologic response rate was 54% overall: 53% for imatinib-resistant patients and 56% for imatinib-intolerant patients. The complete hematologic response rate was 26%. At 12 months, hematologic responses were sustained in 82%. Major cytogenetic responses were seen in 31% (29% imatinib-resistant, 40% imatinib-intolerant), with complete cytogenetic responses in 19%. Overall survival at 12 months was 81%.

Median exposure to nilotinib was 210 days, and the median dose intensity was 781 mg/d. "The fact that the dose intensity is so close to the intended dose indicates how well tolerated this compound is," he said. However, 49% of patients required median dose interruptions of 22 days.

Nilotinib was generally well tolerated. with low rates of grade 3-4 myelosuppression. "Most grade 3-4 myelosuppression occurred within the first cycle," he said.

Dr. le Coutre concluded, "Nilotinib is an effective therapeutic option in this advanced CML population." Major cytogenetic response rates continue to increase with longer follow-up without changes in safety profile, he added.

Recent Videos
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Related Content